Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism

Nephron - Clinical Practice

Volumn 102, Issue 1, 2006, Pages

  Tanaka, Motoko ^a   Itoh, Kazuko ^a   Matsushita, Kazunori ^a   Matsushita, Kazutaka ^a   Fukagawa, Masafumi ^b  

^a Akebono Clinic   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemodialysis; Intravenous maxacalcitol therapy; Percutaneous ethanol injection therapy; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; ALCOHOL; BIOLOGICAL MARKER; CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DOPPLER FLOWMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS PATIENT; HORMONE INHIBITION; HUMAN; MALE; NERVE PARALYSIS; PARATHYROID DISEASE; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REMISSION; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION;

ADULT; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; BONE DENSITY; CALCITRIOL; CALCIUM; COMORBIDITY; DRUG THERAPY, COMBINATION; ETHANOL; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS;

EID: 32844455104     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088163     Document Type: Article

References (37)

1. Malluche HH, Faugere MC: Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990;38:193-211.
2. Parfitt AM: Parathyroid growth: Normal and abnormal; in Bilezikian JP, Marcus R, Levine MA (eds): The Parathyroid: Basic and Clinical Concepts. New York, Raven Press, 1994, p 373.
3. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM: Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001:37:1267-1276.
4. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-E17.
5. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56: 383-392.
6. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000;35:1226-1237.
7. National Kidney Foundation: K/DOQI Clinical Guideline for Bone Metabolism and Disease in chronic kidney disease. Am J Kidney Dis 2003;42(suppl 3):S1-S202.
8. Fukagawa M, Kitaoka M, Tominaga Y, Akizawa T, Kakuta T, Onoda N, Koiwa F, Yumita S, Kurokawa K: Japanese Society for Parathyroid Intervention: Guidelines for percutaneous ethanol injection therapy of the parathyroid glands in chronic dialysis patients. Nephrol Dial Transplant 2003;18(suppl 3):31-33.
9. Fukagawa M, Kazama JJ, Shigematsu T: Management of patients with advanced secondary hyperparathyroidism: the Japanese approach. Nephrol Dial Transplant 2002; 17:1553-1557.
10. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;84: 728-732.
11. Slatopolsky E, Finch J, Brown A: New vitamin D analogs. Kidney Int 2003;85:S83-S87.
12. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K: Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38(suppl 1): S147-S151.
13. Tsukamoto Y, Hanaoka M, Matsuo T, Saruta T, Nomura M, Takahashi Y: Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000;35:458-464.
14. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991;39:874-881.
15. Sato K, Tominaga Y, Ichikawa F, Uchida K, Takezawa J, Tsuchiya T, Kubodera N, Takagi H: In vitro suppression of parathyroid hormone secretion by 22-oxacalcitriol in human parathyroid hyperplasia due to uremia. Nephrology 1998;4:177-182.
16. 3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996;50:34-39.
17. Hirata M, Katsumata K, Masaki T, Koike N, Endo K, Tsunemi K, Ohkawa H, Kurokawa K, Fukagawa M: 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis. Kidney Int 1999;56:2040-2047.
18. 3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion. J Bone Minor Res 2000;15: 175-181.
19. 3 receptor density associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-1443.
20. Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y: Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 2613-2621.
21. Tominaga Y, Grimelius L, Falkmer UG, Johansson H, Falkmer S: DNA ploidy pattern of parathyroid parenchymal cells in renal secondary hyperparathyroidism with relapse. Anal Cell Pathol 1991;3:325-333.
22. Tominaga Y, Tanaka Y, Sato K, Numano M, Uchida K, Falkmer U, Grimelius L, Johansson H, Takagi H: Recurrent renal hyperparathyroidism and DNA analysis of autografted parathyroid tissue. World Surg 1992;16:595-603.
23. Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H: Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13:78-86.
24. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995;95:2047-2053.
25. Koike T, Fukuda N, Fukagawa M, Ohta K, Kurokawa K: Correlation of enhanced cell proliferation with decreased density of vitamin D receptor in situ in parathyroid hyperplasia in chronic dialysis patients. Nephrology 1997;3: 279-284.
26. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81:1598-1606.
27. Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, Drueke TB: Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51: 328-336.
28. Fukagawa M, Kitaoka M, Inazawa T, Kurokawa K: Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens 1997;6: 349-355.
29. Fukagawa M, Tominaga Y, Kitaoka M, Kakuta T, Kurokawa K: Medical and surgical aspects of parathyroidectomy. Kidney Int 1999; 73:S65-S69.
30. Fukagawa M, Kitaoka M, Kurokawa K: Ultrasonographic intervention of parathyroid hyperplasia in chronic dialysis patients: A theoretical approach. Nephrol Dial Transplant 1996;11(suppl 3):125-129.
31. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K: Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994;46:1110-1117.
32. Nakamura M, Fuchinoue S, Teraoka S; Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism. Am J Kidney Dis 2003;42:739-745.
33. Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A: Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999;33:1091-1099.
34. Tanaka R, Kakuta T, Fujisaki T, Tanaka S, Sakai H, Kurokawa K, Saito A: Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography. Nephrol Dial Transplant 2003;18(suppl 3):58-61.
35. de Barros Gueiros JE, Chammas MC, Gerhard R, da Silva Dias Boilesen CF, de Oliveira IR, Moyses RM, Jorgetti V: Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism. Nephrol Dial Transplant 2004;19:657-663.
36. Shiizaki K, Hatamura I, Negi S, Narukawa N, Mizobuchi M, Sakaguchi T, Ooshima A, Akizawa T: Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003;64:992-1003.
37. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.